Wednesday was a busy day for start-up Israeli science and technology firms as BrainStorm Cell Therapeutics, an adult stem cell development company, announced that it had entered into an agreement for a $5m. financing offer from ACCBT Corporation. Correlsense, a business transaction software company, completed a $1.5m. financing agreement with three Israeli investment companies.
BrainStorm, based in Petah Tikva and New York, is currently researching stem cell treatments for Parkinson's disease, ALS (Lou Gehrig's disease) and multiple sclerosis, while Correlsense, based in Herzliya Pituah, enables businesses to better control and monitor computer-based transactions.